Hoy Sheridan M
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2022 Jun;82(9):1017-1023. doi: 10.1007/s40265-022-01734-y.
Oteseconazole (VIVJOA™) is an orally administered azole antifungal agent developed by Mycovia Pharmaceuticals for the treatment of fungal infections. It inhibits cytochrome P450 (CYP) 51, thereby affecting the formation and integrity of the fungal cell membrane, but has a low affinity for human CYP enzymes due to its tetrazole metal-binding group. Oteseconazole is the first agent to be approved (in April 2022) for recurrent vulvovaginal candidiasis (RVVC) in the USA, where it is indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential. Clinical development for the treatment of onychomycosis, and invasive and opportunistic infections is ongoing. This article summarizes the milestones in the development of oteseconazole leading to this first approval for reducing the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential.
奥替康唑（VIVJOA™）是Mycovia制药公司研发的一种口服唑类抗真菌药物，用于治疗真菌感染。它抑制细胞色素P450（CYP）51，从而影响真菌细胞膜的形成和完整性，但由于其四唑金属结合基团，对人CYP酶的亲和力较低。奥替康唑是美国首个获批（2022年4月）用于复发性外阴阴道念珠菌病（RVVC）的药物，适用于有RVVC病史且无生育潜力的女性，以降低RVVC的发病率。治疗甲癣、侵袭性和机会性感染的临床开发正在进行中。本文总结了奥替康唑的研发历程中的里程碑事件，这些事件促成了它首次获批用于降低有RVVC病史且无生育潜力的女性的RVVC发病率。
